Morinaga Milk's New Probiotic Strain, Bifidobacterium breve A1, May Prevent Onset of Alzheimer's Disease
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced the results of a new study investigating the preventive effects of its new probiotic strain Bifidobacterium breve A1 on a model of Alzheimer’s disease. Researchers found that B. breve A1 improved spatial recognition capability, as well as learning and memory capabilities, in cognitively deficient mice, indicating it could play an important role in preventing the onset of Alzheimer’s Disease in humans.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180320005052/en/
(Fig. 1) Effects of B. Breve A1 in improving spatial recognition, learning and memory capabilities (Graphic: Business Wire)
The number of patients affected by dementia is increasing worldwide. One report estimates there were 46.8 million people worldwide living with dementia in 2015 and projects this number will reach 131.5 million by 2050.2 Alzheimer’s disease accounts for a large proportion of dementia cases. Like many chronic diseases, Alzheimer’s develops slowly for several decades before the onset of symptoms, even though deterioration in the brain begins in the early stages. Once the disease has developed, it is difficult to reverse it or even halt its progression; therefore, finding effective countermeasures to prevent the disease’s onset is a top priority for researchers.
The “gut‒brain axis,” which is the functional linkage between the brain and gut microbiota, has attracted attention worldwide. Because probiotics are known to have beneficial effects on gut microbiota, they are a promising treatment for brain health. Indeed, both bifidobacteria and lactobacillus have shown beneficial effects on anxiety and depression.
Building on this research, Morinaga Milk investigated the ability of probiotics to prevent the progression of Alzheimer’s disease in collaboration with Professor Keiko Abe from The University of Tokyo and Kanagawa Institute of Industrial Science and Technology. The study, published in the journal Scientific Reports, revealed the potential of B. breve A1 to prevent the onset of Alzheimer’s disease.
Mice were injected with amyloid β — the substance presumed to cause Alzheimer’s disease — in order to induce cognitive dysfunction in a model of Alzheimer’s disease. Mice in the active treatment group were administered B. breve A1 (1 × 109 per day) orally for 10 days (B. breve A1 group). Mice in the control group were given either saline (saline group) or a cholinesterase inhibitor, a medication prescribed for dementia (positive control group). Cognitive function was evaluated by a Y maze test and a passive avoidance test.
Y maze Behavioral Test Confirms Improvement of Spatial Recognition Capability
“Spontaneous alternation” refers to the tendency of normal mice to choose a different path when navigating a maze than the last one chosen, indicating they remember what paths they have already tried. In this study, amyloid β injected mice given saline showed a remarkable reduction in spontaneous alternation rate in the Y maze test compared to normal mice. However, the B. breve A1 group showed a significant improvement in spontaneous alternation rate compared to the saline group. These results indicate that B. breve A1 improves spatial recognition capability (Fig. 1, left).
Passive Avoidance Behavioral Test Reveals Improvement in Learning and Memory Capability
During the passive avoidance test, mice need to learn to avoid a negative stimulus by staying away from a certain area. If they do so successfully, it indicates they remember the negative experience. Similar to the Y maze behavioral test, mice in the B. breve A1 group stayed longer in the area without a negative stimulus compared to the saline group. This result indicates that B. breve A1 improves learning and memory capabilities (Fig. 1, right).
B. breve A1 Nearly as Effective as Common Alzheimer’s Drug
The improvements in both the Y maze test and the passive avoidance test were similar in magnitude to those observed in the positive control group treated with a cholinesterase inhibitor, a medication commonly prescribed for Alzheimer’s disease, indicating that B. breve A1 has similar potential to improve amyloid-induced cognitive impairment.
Hippocampus Gene Expression is Key Behind Mechanism of Action
Morinaga Milk focused on the hippocampus, the area of the brain associated with memory and learning capabilities, by performing comprehensive gene expression analysis in the hippocampus of the mice. The researchers found the expression of many genes was altered; particularly, gene groups associated with immunological reactions and inflammation were changed, causing immunological abnormalities and excessive inflammation in the impaired mice ingesting saline. In contrast, the expression of the majority of these genes remained normal in impaired mice ingesting B. breve A1 (Fig. 2).
These findings led Dr. Jin-zhong Xiao, General Manager of Morinaga Milk’s Next Generation Science Institute, to state that “Intake of B. breve A1 suppressed excessive immunological reactions and inflammation in the brains of the mice and improved cognitive function.” He went on to add, “Chronic inflammation of the brain is characteristic of Alzheimer’s disease. B. breve A1’s ability to suppress inflammation in the hippocampus is the key behind its ability to prevent progression of the disease.” The company plans to continue to research the effects of B. breve A1 on human subjects to further explore its therapeutic potential for preventing Alzheimer’s disease onset.
About Morinaga Milk
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan. Morinaga Milk started research on bifidobacteria in the 1960s, inspired by the fact that bifidobacteria are the predominant bacteria residing in the intestines of breast-fed infants. In 1969, Morinaga Milk isolated its flagship strain Bifidobacterium longum BB536 from an infant. Morinaga Milk excels in innovative technology and offers various dairy products and other beneficial functional ingredients to customers around the world.
|1.||Y. Kobayashi et al. Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Scientific Reports 7(1). Dec. 2017.|
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL16.8.2018 22:02 | Tiedote
Manchester United (NYSE:MANU) has today announced a major milestone on its digital transformation journey with HCL Technologies, with the successful launch of the Manchester United Official app powered by HCL’s digital experience platform. The launch is part of the ongoing digital transformation of the club to provide a real-time, engaging, personalized, and unified experience to Manchester United’s 659 million global followers, which supports the club’s strategy to become a Digital Sports Enterprise. At the heart of this transformation is the digital platform developed by HCL, providing the club with a single view of fans across web and app touchpoints, offering fans a one-stop shop for everything Manchester United. Manchester United’s Group Managing Director Richard Arnold comments: “This app will allow our 659 million Manchester United followers to easily connect to the club they love, wherever they are in the world. Fans will now have the opportunity to follow all Manchester United
4K 4Charity Fun Run Announces Open Registration for IBC201816.8.2018 20:41 | Tiedote
AWS Elemental, an Amazon Web Services (AWS) company, today announced that the fifth annual 4K 4Charity Fun Run at IBC Show will take place at 7:00 a.m. local time on Saturday, Sept. 15 at Amstelpark in Amsterdam. Registration is open at https://4k4charity.com/ibc. Among the non-profits supported by the 4K 4Charity Fun Run at IBC Show is Amsterdam-based StichtingNewTechKids, which provides computer science education for girls, minorities, and economically challenged youth in the Netherlands. The organization supports a computer science teacher training program for primary school teachers with proceeds from 4K 4Charity. Also supported is Iridescent, a global education non-profit that empowers underrepresented young people to become innovators and leaders through engineering and technology. Through their two programs, Curiosity Machine AI Family Challenge and Technovation, Iridescent introduces underserved communities to new technologies and empowers and equips them to apply those technol
2018 D.I.C.E. Cannes Announced Round 3 Speakers16.8.2018 17:01 | Tiedote
The Academy of Interactive Arts & Sciences’ D.I.C.E. Cannes event will take place 9-11 September 2018 at the Hotel Barrière Le Majestic Cannes in France. Leading video game executives will participate in the premier networking opportunities, listen to key speakers address the conference theme - Trailblazers - to tackle some of the industry’s biggest ideas and trends. Newly announced speakers include: Craig Duncan, Studio Head at Rare – Duncan will share his studio’s experience and learnings with “A Rare Voyage of Adventure.” Duncan will provide insight into Rare’s bold new IP Sea of Thieves, a game that has inspired friendships and players creating stories together. David Hubert, Animation and Cinematic Director at Eidos Montreal – In Hubert’s talk he will discuss how cinematics are redefining AAA story-driven games and how they will continue to shape the medium to push the envelope throughout the production process. Adam Orth – In a session titled “Digging for Fire: Virtual Reality 20
GN Hearing and Google Announce Partnership to Bring Direct Mobile Streaming from Android Devices to Hearing Aids16.8.2018 16:00 | Tiedote
GN Hearing and Google have today announced a new technology partnership that will make GN Hearing the first manufacturer to enable a full spectrum of direct audio streaming from Android devices to hearing aids. The expectations are that direct streaming will become available to hearing aid users of the recently launched hearing aids ReSound LiNX Quattro™ and Beltone Amaze™ in a future Android release. “According to the World Health Organization, around 466 million people worldwide have disabling hearing loss. This number is expected to increase to 900 million people by the year 2050. Google is working with GN Hearing to create a new open specification for hearing aid streaming support on future versions of Android devices,” states Seang Chau, Vice President of Engineering at Google. Users will be able to connect and monitor their hearing aids, so they can get the full advantages of their Android devices without using an intermediate device for streaming to their hearing aids. This will
Zurich Expands Global Use of Guidewire InsurancePlatform with Selection of Guidewire Cyence Risk Analytics16.8.2018 15:55 | Tiedote
Guidewire Software, Inc. (NYSE: GWRE), the provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Zurich Insurance Group (Zurich) has selected Guidewire Cyence™ Risk Analytics (Cyence) to leverage the cyber risk knowledge and insights the solution provides to help the company prospect, underwrite, and price risks. Zurich will roll out Cyence globally with an emphasis on enhanced analytics and intelligence for risk selection. Unprecedented technological advances of the 21st century have shifted the nature of risk across the P&C insurance industry. Ever-evolving cyber risks present unique challenges including limited availability of traditional actuarial data needed to model these risks. Cyence combines economic modeling, cybersecurity, machine learning and Internet scale data collection to help risk takers assess the financial impact of cyber risk. “After conducting a thorough search, we found that the capabilities of Guidewire Cyence Risk
Scientist.com Named One of America’s Ten Fastest-Growing Private Companies by Inc. Magazine16.8.2018 15:06 | Tiedote
Scientist.com, the world’s leading marketplace for outsourced scientific services, today announced that it ranked no. 9 on Inc. magazine’s 2018 list of the 5,000 fastest-growing, privately owned companies in America. Scientist.com ranked no. 2 nationally in the Health category and no. 2 in the state of California. The San Diego-based company builds private marketplaces that connect life science research organizations with a global network of over 2,600 contract research organizations (CROs) and providers of scientific services. “Our mission is to empower and connect scientists worldwide and make it possible to cure all human diseases by 2050,” stated Kevin Lustig, Scientist.com’s CEO and Founder. “On Scientist.com, a single, highly trained scientist can run an entire drug discovery program from concept to clinic from his or her laptop without ever physically entering a laboratory.” The pharmaceutical industry spends about $150B a year on medical research and produces about 25 new medic
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme